Fresenius Medical Care sends more Novalung consoles for ECMO to support Wuhan in battle against COVID-19

Fresenius Medical Care is again supplying medical equipment that is urgently needed to combat the COVID-19 outbreak in Wuhan, including 16 Novalung® consoles, the second such shipment to the Chinese city. Novalung is an extracorporeal membrane oxygenation (ECMO) system from Fresenius Medical Care that pumps and oxygenates a patient’s blood. ...

The US FDA (Food and Drug Administration) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for patients with acute lung failure or acute cardiopulmonary failure. The FDA announced this on Friday evening. With class ...

ESICM congress LIVES 2019, Berlin

ESICM’s annual congress, LIVES, attracts audiences of over 6,000 physicians, anaesthetists, trainees and nursing and allied health professionals, every year, from every continent and 97 different countries. Xenios - a Fresenius Medical Care company, was part of the Society’s 32nd annual congress at the CityCube, Berlin from 28 September – ...

ERS 2019, Madrid

The annual ERS Congress is a showcase of excellence across the entire field of respiratory Medicine. ERS International Congress 2019 was hosted in Madrid, Spain from 28 September to 2 October 2019 at IFEMA. This year, the Congress gathered more than 20,000 delegates over five days to witness more than ...

Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care. Novalung was established in 2003 and specialises in the treatment ...

Synchronized cardiovascular support now ready for the market

Xenios AG concludes its first clinical study on i-cor Synchronized Cardiac Assist, documenting the safety and feasibility of the synchronized cardiovascular support system. During the “SynCor” trial, a multicentre study treated 47 patients in nine different German clinics using an innovative pulsatile, cardiac-synchronous circulatory support system. The aim of the ...